Oramed Pharmaceuticals Inc. (ORMP): Nadav Kidron , CEO of Oramed Pharmaceuticals Inc. purchased 1,000 shares on May 12, 2016. The Insider buying transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $6.98 per share for a total value of $6,953.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 14, 2016, Harold Jacob (director) sold 8,500 shares at $6.45 per share price.On Dec 31, 2015, Miriam Kidron (Chief Technology Officer) sold 50,000 shares at $8.98 per share price.Also, On Dec 10, 2015, Michael Berelowitz (director) sold 700 shares at $9.44 per share price.On May 12, 2015, Nadav Kidron (CEO) purchased 600 shares at $6.61 per share price.
Shares of Oramed Pharmaceuticals (ORMP) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.22 points or -2.37% at $9.07 with 67,990 shares getting traded. Post opening the session at $9.29, the shares hit an intraday low of $8.89 and an intraday high of $9.3099 and the price vacillated in this range throughout the day. The company has a market cap of $119 M and the number of outstanding shares has been calculated to be 1,31,15,991 shares. The 52-week high of Oramed Pharmaceuticals is $10.74 and the 52-week low is $4.15.
Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Orameds flagship product an orally ingestible insulin capsule in phase II clinical trials is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Orameds delivery platform protects protein sand enhances their absorption allowing them to reach the blood stream through the portal vein. The Companys products include ORMD-0801 Oral insulin capsule; ORMD 0901 Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.